Walk through almost any supplement aisle and the language begins to blur.
Products claim to:
- Support energy
- Promote healthy ageing
- Maintain cellular health
- Support cognitive function
- Strengthen immunity
- Improve overall wellbeing
These statements sound scientific, but they rarely tell the consumer:
- How large the effect is
- Which dose produced it
- How quickly it occurred
- What was measured
- Which study supports the claim
Tru Niagen stands out because its central claim is unusually specific.
The brand says that daily supplementation with its patented form of nicotinamide riboside—Niagen NR can increase blood levels of nicotinamide adenine dinucleotide, or NAD+, by:
- More than 50% with 300 milligrams daily
- Up to 150% with 1,000 milligrams daily
Unlike a generic "supports cellular energy" statement, those numbers can be traced to a published randomised clinical trial.
The underlying study reported average increases of:
- 22% with 100 milligrams
- 51% with 300 milligrams
- 142% with 1,000 milligrams
after two weeks of supplementation. The increases remained elevated during the rest of the eight-week trial.
That makes Tru Niagen's claim unusually measurable.
It does not necessarily make every broader health implication equally proven.
This is one signal from the Consensys Innovation Signals Engine, which continuously scans a library of more than one million products worldwide for emerging shifts in formulation, positioning and consumer demand.
Signal: Quantified Biomarker Marketing
The claim comes from a real dose-ranging trial
The most relevant study was published in 2019.
It was an eight-week:
- Randomised trial
- Double-blind trial
- Placebo-controlled trial
- Dose-ranging study
The participants were overweight but otherwise generally healthy adult men and women.
They received one of four daily regimens:
- Placebo
- 100 milligrams of nicotinamide riboside
- 300 milligrams
- 1,000 milligrams
Researchers measured whole-blood NAD+ and related metabolites.
Within two weeks, the study found a clear dose-response relationship:
- Daily nicotinamide riboside dose
- Average whole-blood NAD+ increase
- 100 mg
- 22%
- 300 mg
- 51%
- 1,000 mg
- 142%
The increases were maintained through the remaining study period.
Product: Tru Niagen
Company: Niagen Bioscience, formerly ChromaDex
Active Ingredient: Niagen nicotinamide riboside chloride
Primary Measured Outcome: Whole-blood NAD+
Innovation Type: Dose-Specific Biomarker Substantiation
The brand's percentages are rounded versions of the study
Tru Niagen currently says:
- 300 milligrams increases NAD+ by over 50%
- 1,000 milligrams increases NAD+ by up to 150%
The published study found 51% and 142%.
The brand is therefore not inventing two arbitrary percentages.
It is translating the study into simpler consumer language:
- 51% becomes "over 50%"
- 142% becomes "up to 150%"
Tru Niagen also links the claims to a time period of approximately two to three weeks, consistent with the clinical findings that blood NAD+ rose rapidly and remained elevated with continued daily use.
Evidence Signal: Marketing Claim Closely Tracks Published Result
The 1,000-milligram claim should still be read as up to 150%, not as a guaranteed 150% increase for every individual.
Biological responses vary.
What is NAD+?
NAD+ is a molecule found in living cells.
It plays essential roles in processes including:
- Cellular energy metabolism
- Oxidation-reduction reactions
- DNA-repair signalling
- Cellular stress responses
- Enzyme activity
- Mitochondrial function
The body can produce NAD+ through several biochemical pathways using vitamin B3-related compounds.
Nicotinamide riboside is one such precursor.
After consumption, the body can convert NR through metabolic pathways that contribute to the NAD+ pool.
Human pharmacokinetic research has shown that oral NR alters the blood NAD+ metabolome in a dose-dependent manner. A 2016 study found that single doses of 100, 300 and 1,000 milligrams produced measurable changes in NAD+-related metabolites.
Innovation Type: Measurable Precursor-to-Biomarker Pathway
This creates a relatively clear chain:
Consume NR → body metabolises NR → blood NAD+ increases
That chain is easier to measure than a subjective statement such as "feel more energised."
Raising NAD+ is not the same as proving a health benefit
This is the most important distinction in the article.
The clinical evidence strongly supports the narrower claim:
Oral nicotinamide riboside can raise NAD+ and related metabolites in humans.
The evidence is much less conclusive for broader claims such as:
It makes healthy consumers feel more energetic.
It reverses ageing.
It improves memory.
It causes weight loss.
It extends human lifespan.
It prevents age-related disease.
It improves exercise performance in everyone.
Recent scientific reviews conclude that NAD+-raising supplements demonstrate clear biological activity, but evidence for general anti-ageing and wellness outcomes in humans remains inconclusive. Larger and longer studies are still needed.
Evidence Distinction: Biomarker Change Versus Consumer Outcome
A product can successfully change a molecule in the blood without producing a noticeable benefit for every user.
The brand has chosen a claim it can measure precisely
Most supplement benefits are difficult to quantify.
Consider the claim:
- "Supports energy."
- What would prove it?
Researchers could measure:
- Self-reported tiredness
- Exercise output
- Mitochondrial respiration
- Daily physical activity
- Work performance
- ATP production
- Sleep quality
Each would produce a different answer.
By contrast, measuring blood NAD+ produces one defined numerical endpoint.
This gives Tru Niagen a marketing advantage.
The company can state:
- A dose
- A percentage
- A timeline
- A named biomarker
- A peer-reviewed study
- Innovation Type: Biomarker-Led Claim Architecture
The claim feels more pharmaceutical than traditional supplement language, even though Tru Niagen remains a dietary supplement.
Specificity can make a claim appear stronger than it really is
A precise percentage creates authority.
Consumers often assume that a statement containing a number must be more meaningful than a general claim.
But precision and importance are different.
For example:
"Raises blood NAD+ by 51%"
is highly specific.
It does not tell the consumer:
- Whether they were deficient initially
- Whether the increase occurred in every tissue
- Whether the change improved their daily functioning
- Whether a larger increase is necessarily better
- Whether the effect persists after stopping
- Whether long-term use changes disease risk
- Risk Signal: Biomarker Precision Creating Outcome Certainty
The number is reliable only for the endpoint actually measured.
Blood NAD+ may not represent every organ equally
The pivotal dose-ranging trial measured whole-blood NAD+.
That is a legitimate biological measurement.
But NAD+ metabolism differs across tissues.
An increase in blood does not automatically mean an identical percentage increase in:
- Brain
- Skeletal muscle
- Liver
- Heart
- Skin
- Adipose tissue
Other human studies have investigated tissue-specific effects.
A 2020 trial found that 1,000 milligrams of NR daily increased NAD+-related metabolites in skeletal muscle among overweight or obese adults. However, it reported few broader metabolic-health effects.
A 2024 preliminary study also found that acute NR supplementation could increase measurable cerebral NAD+ in healthy volunteers, but the research was exploratory and not proof of a long-term cognitive benefit.
Evidence Signal: Biological Activity Across More Than Blood
Evidence Gap: Consistent Whole-Body Functional Benefit
Human trials have produced mixed health outcomes
Several clinical trials confirm that NR is biologically active and generally well tolerated at studied doses.
But downstream outcomes have been inconsistent.
Healthy middle-aged and older adults
A randomised crossover trial found that chronic NR supplementation elevated NAD+ metabolism and was well tolerated. It identified preliminary cardiovascular signals that required confirmation in larger trials.
Overweight and obese men
A placebo-controlled trial found that NR was safe but did not produce the expected improvements in insulin sensitivity and several metabolic outcomes.
Skeletal muscle
A separate study found increased muscle NAD+ metabolites but few major improvements in metabolic health.
Mild cognitive impairment
Research found that NR increased blood NAD+, but the study did not show a clear improvement in cognition.
Long COVID
A 2025 study reported higher NAD+ levels but no meaningful improvement in cognitive functioning.
Evidence Signal: Reliable Biomarker Response, Variable Clinical Response
This pattern explains why the brand's most defensible quantified claim remains the NAD+ increase itself.
Why most supplement brands avoid precise percentages
There are several reasons the rest of the category relies on language such as "supports" and "helps maintain."
The ingredient may not produce one consistent measurable effect
A multivitamin contains many nutrients, each affecting different pathways.
There may be no single biomarker that summarises the product.
Baseline status changes the result
A person deficient in vitamin D may respond differently from someone whose level is already adequate.
Consumer outcomes are subjective
Energy, focus, mood and wellbeing are difficult to measure consistently.
Clinical trials are expensive
Dose-ranging, placebo-controlled research requires:
- Participant recruitment
- Laboratory testing
- Study monitoring
- Statistical analysis
- Publication
- Regulatory and legal review
- Precise claims create legal exposure
If a brand says a product "increases energy by 42%," regulators and competitors can ask exactly how that percentage was established.
Results may not be commercially impressive
A study might find no meaningful difference, or an effect too small to justify the product's price.
Market Signal: Vagueness Reduces Evidentiary Risk
"Supports energy metabolism" is easier to defend than "makes consumers 30% more energetic."
The US supplement framework encourages structure-function language
US dietary supplements can make certain structure-function claims without receiving premarket approval for treating disease.
These include statements such as:
- Supports cellular energy
- Helps maintain healthy ageing
- Supports normal immune function
Such statements must carry the familiar disclaimer that they have not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure or prevent disease.
Tru Niagen uses this structure-function framework for its wider benefits while anchoring the brand in a more precise biomarker claim. Its professional materials display the required FDA disclaimer alongside cellular-health and metabolic-support language.
Claim Strategy: Precise Biomarker Plus Broad Structure-Function Benefits
This is commercially effective because the percentage provides scientific specificity while the broader language connects the biomarker to consumer aspirations.
The pivotal trial had commercial connections
The dose-ranging study is peer-reviewed, randomised and placebo-controlled.
That makes it considerably stronger than an unsupported brand testimonial.
It should still be read with attention to funding and author relationships.
The trial studied the company's proprietary nicotinamide riboside ingredient, and the publication disclosed commercial connections involving ChromaDex.
Industry participation does not automatically invalidate research.
Companies frequently fund studies of ingredients they developed because they have the strongest financial incentive to do so.
But independent replication strengthens confidence.
Evidence Principle: Peer Review Does Not Eliminate Funding Context
The ideal evidence base includes:
- Company-funded studies
- Independent university studies
- Replication by unrelated researchers
- Different populations
- Different laboratories
- Published null results as well as positive findings
- "Patented" describes ownership—not necessarily superiority
Tru Niagen uses Niagen, a patented nicotinamide riboside chloride ingredient.
A patent can protect:
- A composition
- A manufacturing method
- A crystalline form
- A use
- Intellectual property around production
It does not automatically prove that the ingredient produces better health outcomes than every unpatented alternative.
Trust Distinction: Patent Protection Versus Clinical Superiority
The commercially relevant advantage is that ChromaDex can connect:
- A defined ingredient identity
- Manufacturing control
- Human clinical trials
- Dose-specific product formats
- Regulatory documentation
That creates a more traceable evidence system than a generic "NAD booster" with unclear sourcing.
The company now operates as Niagen Bioscience
ChromaDex has increasingly presented its consumer and scientific platform under the Niagen Bioscience identity.
The company markets:
- Tru Niagen 300 mg
- Tru Niagen Pro 1,000 mg
- Additional beauty, immune and practitioner-focused products
Its core strategy is to make Niagen NR the recognised branded ingredient behind NAD+ supplementation.
Brand Architecture: Ingredient Brand Plus Consumer Brand
Niagen is the patented ingredient platform.
Tru Niagen is the consumer supplement brand.
Niagen Bioscience is the broader company and science identity.
The Nobel Prize association is real—but must be explained carefully
The original finding says Tru Niagen is backed by a named Nobel Prize-winning biochemist.
That is accurate, but potentially misleading without context.
Niagen Bioscience lists Nobel laureates Roger Kornberg and Sir John Walker on its scientific advisory board.
Roger Kornberg, a Stanford structural biologist and winner of the 2006 Nobel Prize in Chemistry, is presented as chairman of the company's scientific advisory board. Sir John Walker received the 1997 Nobel Prize in Chemistry for work involving the enzymatic mechanism underlying ATP synthesis.
Trust Signal: Nobel Laureates on Scientific Advisory Board
This does not mean:
The Nobel Prize was awarded for Tru Niagen.
The Nobel committee endorses the product.
The advisers personally conducted every clinical trial.
Their status proves every marketing claim.
Evidence Correction: Advisory Role, Not Nobel Validation of Product
The precise wording should be:
Niagen Bioscience's scientific advisory board includes Nobel Prize-winning scientists.
Not:
Tru Niagen won Nobel Prize-backed proof.
The central NR discovery came from Charles Brenner
The company's chief scientific adviser, Charles Brenner, is associated with foundational research establishing nicotinamide riboside as an NAD+ precursor pathway.
His work helped show how cells can convert NR into NAD+ through a pathway involving nicotinamide riboside kinases.
Niagen Bioscience prominently uses Brenner's expertise within its scientific identity.
Science Signal: Founder-Level Connection to NAD+ Pathway Research
Again, scientific leadership should support—not replace—product-specific evidence.
A 150% increase sounds larger than it is intuitively
Percentage language can create confusion.
Suppose a person begins with a blood NAD+ measurement represented as 100 units.
A 142% increase would mean the value rises by 142 units to approximately 242 units.
The consumer might incorrectly interpret "150%" as:
- 150% healthier
- 150% more energy
- 150% younger cellular function
- 150% improvement in lifespan
None follows from the study.
Consumer Education Signal: Percentage Applies Only to NAD+ Measurement
The strongest responsible claim states both:
- The magnitude
- The endpoint
For example:
- "Increased whole-blood NAD+ by an average of 51% at 300 mg daily."
- A higher NAD+ increase is not automatically a better consumer choice
The trial demonstrated a dose-response relationship.
That does not mean every healthy consumer should choose the highest dose.
A larger dose may involve:
- Higher cost
- More capsules
- Different suitability
- Greater need for professional guidance
- Limited additional proven consumer benefit
The 1,000-milligram product creates a larger biomarker increase than the 300-milligram product.
But available evidence does not establish that the average healthy consumer receives three times the practical benefit.
Risk Signal: Dose Escalation Based on Biomarker Alone
Consumers should not assume that the largest number is automatically the optimal routine.
Safety data are stronger than efficacy data for many outcomes
Human trials have generally found NR to be well tolerated at commonly studied doses.
Studies have investigated:
- 300 milligrams daily
- 1,000 milligrams daily
- 2,000 milligrams daily
- Higher short-term clinical doses
A 2023 trial reported that 3,000 milligrams daily for 30 days was tolerated in the studied Parkinson's disease population, although such research should not be interpreted as a general consumer dosage recommendation.
The evidence supports a narrower conclusion:
NR has demonstrated reasonable short-term tolerability across multiple clinical studies.
Long-term use across broad healthy populations still requires continued monitoring and research.
Tru Niagen provides a model for better supplement claims
The strongest lesson is not that every supplement should promise a dramatic percentage.
It is that claims should be connected to an evidence chain.
A useful claim should state:
- What was consumed?
- At what dose?
- For how long?
- What was measured?
- How much did it change?
- Who participated?
- Was there a placebo group?
- Was the result peer reviewed?
- Who funded the research?
- Does the measured change correspond to a proven consumer benefit?
- Innovation Territory: Evidence-Traceable Supplement Marketing
Tru Niagen performs particularly well on questions one through five.
Questions nine and ten still require careful interpretation.
How consumers should read this claim
The claim can be divided into three levels.
Strongly supported
Daily nicotinamide riboside supplementation increases blood NAD+ in a dose-dependent manner.
Plausible but broader
Increasing NAD+ may support cellular metabolic processes in which NAD+ participates.
Not established for the average healthy consumer
The product reverses ageing, extends lifespan or produces a guaranteed noticeable increase in energy.
Evidence Framework: Proven → Plausible → Unproven
This framework is useful across the supplement category.
The one specific claim reveals the category's larger problem
Tru Niagen can state a percentage because the company chose a measurable intermediate endpoint.
Most supplements remain trapped between two extremes:
- Vague claims that are difficult to disprove
- Disease claims they are not legally allowed to make
Quantified biomarkers offer a third route.
Future supplement brands may increasingly claim:
- Change in blood nutrient level
- Change in microbiome composition
- Change in inflammatory marker
- Change in sleep measurement
- Change in glucose response
- Change in verified deficiency status
But the industry must avoid turning every measurable biomarker into a promise of transformation.
Market Signal: Biomarkers Becoming Marketing Assets
The real standard should be specificity with restraint
Tru Niagen deserves credit for connecting its primary claim to:
- A defined ingredient
- A defined dose
- A defined timeframe
- A defined measurement
- A peer-reviewed trial
That is considerably more transparent than saying only:
"Supports energy."
The responsible interpretation is equally specific.
The product has been shown to raise NAD+.
It has not been shown to make every healthy consumer feel 50% better.
The most scientifically credible supplement claim, like Tru Niagen's, is not necessarily the most exciting one.
It is the one that tells consumers exactly what changed—and refuses to imply that everything else changed with it.
Brand Radar Signal Tags
Brands and Organisations
Tru NiagenNiagenNiagen BioscienceChromaDexCharles BrennerRoger KornbergSir John WalkerStanford UniversityUniversity of Colorado Boulder
Products
Tru Niagen 300 mgTru Niagen Pro 1,000 mgNiagen Nicotinamide Riboside ChlorideNicotinamide Riboside Supplement
Ingredients and Biomarkers
Nicotinamide RibosideNRNAD+Nicotinamide Adenine DinucleotideVitamin B3 PrecursorWhole-Blood NAD+NAD+ MetabolomeNAAD
Quantified Claims
22% NAD+ Increase at 100 mg51% NAD+ Increase at 300 mg142% NAD+ Increase at 1,000 mgDose-Dependent NAD+ IncreaseIncrease Within Two WeeksSustained Eight-Week Increase
Innovation Types
Quantified Biomarker MarketingDose-Specific Clinical ClaimBiomarker-Led Claim ArchitectureEvidence-Traceable Supplement MarketingPatented Ingredient PlatformIngredient Brand Plus Consumer Brand
Evidence Signals
Randomised TrialDouble-Blind TrialPlacebo-Controlled TrialDose-Ranging TrialPeer-Reviewed Human ResearchWhole-Blood MeasurementHuman Pharmacokinetic EvidenceMultiple Clinical TrialsCommercial Funding Context
Consumer Benefits and Claims
Cellular Energy SupportCellular HealthHealthy Ageing SupportMetabolic SupportNAD+ Replenishment
Evidence Limitations
Biomarker Is Not Clinical OutcomeBlood Does Not Represent Every TissueHuman Health Outcomes Are MixedAnti-Ageing Effect Not EstablishedLifespan Extension Not ProvenSubjective Energy Benefit Not QuantifiedHigher Dose Does Not Guarantee Greater Practical Benefit
Trust Signals
Nobel Laureate Scientific AdvisersRoger Kornberg Advisory Board ChairmanSir John Walker Advisory Board MemberCharles Brenner Scientific AdviserPatented IngredientPublished Dose Response
Risk Signals
Nobel Association OverstatementPercentage Claim MisinterpretationBiomarker Precision Creating Outcome CertaintyDose EscalationStructure-Function Claim ExpansionPatent Mistaken for SuperiorityIndustry-Funded Research
Sources
Core dose-ranging clinical trial
Conze et al., 2019 — Safety and Metabolism of Long-Term Administration of Nicotinamide Riboside: The eight-week randomised, double-blind, placebo-controlled trial reported whole-blood NAD+ increases of 22%, 51% and 142% at 100, 300 and 1,000 milligrams daily.
Human pharmacokinetic and clinical evidence
Trammell et al., 2016: Demonstrated dose-dependent changes in the human blood NAD+ metabolome following single oral doses of 100, 300 and 1,000 milligrams of NR.
Martens et al., 2018: Found that chronic NR supplementation elevated NAD+ metabolism and was well tolerated in healthy middle-aged and older adults.
Dollerup et al., 2018: Found safety and biological activity but no clear improvement in several metabolic outcomes among obese men.
Remie et al., 2020: Reported increased skeletal-muscle NAD+ metabolites but few other major metabolic-health effects.
Wu et al., 2023: Found increased blood NAD+ in older adults with mild cognitive impairment but no improvement in cognition.
Nanga et al., 2024: Provided preliminary evidence that acute NR supplementation can increase cerebral NAD+ in healthy people.
Reviews of health benefits and limitations
Damgaard et al., 2023: Reviews human NR research and identifies the difference between reliable NAD+ elevation and less certain clinical effects.
Freeberg et al., 2023: Concludes that NAD+ precursors are generally tolerable and raise NAD+-related metabolites, while physiological benefits vary across studies.
2026 review of NAD+ supplementation for wellness and anti-ageing: Concludes that biological activity is clear but anti-ageing and general wellness effectiveness remain inconclusive.
Official product and scientific-advisory information
Tru Niagen product information: Uses the consumer-facing claims of more than 50% NAD+ increase with 300 milligrams and up to 150% with 1,000 milligrams. https://www.truniagen.com/products/tru-niagen-1000mg
Niagen Bioscience scientific team: Lists Nobel laureates Roger Kornberg and Sir John Walker on the scientific advisory board and Charles Brenner as chief scientific adviser.